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Abstract: Even after complete surgical resection of pulmonary
metastases, many patients develop recurrent disease in the thorax
despite the use of systemic chemotherapy, dosage of which is
limited because of systemic toxicity. Although subsequent opera-
tions are feasible and good long-term results have been reported,
sufficient functional lung parenchyma must remain. For this reason,
new treatment strategies are explored. Similar to isolated limb and
liver perfusion, isolated lung perfusion (ILuP) is a promising surgi-
cal technique for the delivery of high-dose chemotherapy with
minimal systemic toxicity. The use of biologic response modifiers,
such as tumor necrosis factor, is also feasible. ILuP with high-dose
chemotherapy has proven to be highly effective in the experimental
models of pulmonary metastases with a superior survival advantage
compared with systemic treatment. Lung levels are significantly
higher after ILuP compared with intravenous therapy without sys-
temic exposure. Phase I human studies have shown that ILuP is
technically feasible with low morbidity and without compromising
the patient’s pulmonary function. Further clinical studies are neces-
sary to determine its definitive effect on local recurrence, long-term
toxicity, pulmonary function, and survival.
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A lot of experimental animal research has been performeddemonstrating that doxorubicin, melphalan, cisplatin, flu-
orouracil, paclitaxel, and gemcitabine are effective drugs for
the locoregional treatment of pulmonary metastases by iso-
lated lung perfusion (ILuP) or pulmonary artery infusion.1
This experimental work demonstrates that it is feasible to
deliver high-dose chemotherapy to the lung with minimal
systemic exposure. It provides a solid basis for the clinical
studies that have been performed over the last decades.2
Most of these studies use the setting of ILuP, and only
one clinical study on chemoembolization has been published.
So far, regional blocked perfusion systems have only been
applied in experimental animal studies. These different tech-
niques will be discussed separately with the main emphasis
on ILuP.
CHEMOEMBOLIZATION
Transpulmonary chemoembolization was evaluated in
one clinical study including 23 patients with 26 unresectable
lung metastases.3 Mitomycin C was injected together with
iodized oil and microsphere particles by means of a transpul-
monary approach with balloon protection. There were no
major side effects or complications. Volume regression of the
metastases was achieved in eight patients and stable disease
in six patients. Progressive disease was observed in nine
patients. Further clinical studies are awaited for to determine
whether chemoembolization is a valid treatment option for
the patients with pulmonary metastases.
REGIONAL BLOCKED PERFUSION SYSTEMS
In an experimental setting, different modalities of cy-
tostatic lung perfusion were compared with respect to plasma
and tissue drug concentrations to assess the efficacy of an
endovascular blood flow occlusion (BFO) technique.4 In this
thoracotomy-free BFO perfusion system, the mean lung tis-
sue doxorubicin concentration reached the same level as it did
in an ILuP setting, whereas the systemic (intravenous) appli-
cation of doxorubicin resulted in 6- to 9-fold lower tissue
levels. Systemic plasma levels during and after BFO perfu-
sion were much lower than in the intravenous group. Also,
gemcitabine can be used in this setting with no difference in
lung levels after BFO compared with ILuP.5 Even if endo-
vascular BFO might be a promising technique for repeated
cytostatic lung perfusion, so far no data on clinical studies
using this method are available.
ISOLATED LUNG PERFUSION
The number of human studies on ILuP is limited at the
present time. As it is difficult to extrapolate the results of
animal studies into a clinical setting, most protocols in pa-
tients study the feasibility of ILuP in resectable or unresect-
able lung metastases and try to determine the toxicity and the
maximal tolerated dose (MTD) of the chemotherapeutic agent
used in ILuP.
One of the first reports of clinical ILuP was published
in 1958 by Creech et al.6 He investigated ILuP as a prophy-
lactic therapy before radical operation of extremity sarcoma,
but no further studies followed, although a survival difference
was seen. Next, Minchin et al.7 reported on ILuP with
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doxorubicin in three patients. No systemic leakage was
present while increasing lung levels of doxorubicin with
longer perfusion times were seen. Johnston et al. continued
experimental work with doxorubicin and performed both
single and total lung perfusion in patients with inoperable
pulmonary metastases and primary lung cancer.7,8 Specific
technical details are provided in a recent review.9 Results of
a literature search on clinical studies of ILuP is provided in
Figure 1, and studies from 1995 onward are summarized in
Table 1.
Doxorubicin
Johnston et al.8 conducted a pilot study treating four
patients with pulmonary metastatic sarcoma and four patients
with diffuse bronchoalveolar carcinoma with doxorubicin and
cisplatin through ILuP. Six patients were perfused with doxo-
rubicin and two with cisplatin. The latter is discussed in the
paragraph on cisplatin.
Single left lung perfusion was performed in three pa-
tients and total lung perfusion in five patients. Perfusion time
ranged from 45 to 60 minutes at ambient or normothermic
temperatures, except for one patient who underwent perfu-
sion at moderate hyperthermia of 40°C. Escalating doses of
doxorubicin were used, ranging from 1 to 10 g/mg perfus-
ate. Doxorubicin values in the systemic circulation were
minimal with a peak systemic value of 0.23 g/ml. Pulmo-
nary perfusate drug concentrations were higher with increas-
ing doxorubicin dosages. Peak concentration in the perfusate
was 3.08 g/ml. Drug tissue levels in the escalating doxoru-
bicin group tended to increase with higher dosage in contrast
to the two patients treated with cisplatin. Maximal concen-
tration of doxorubicin was 2.81 g/g in the lung and tumor
tissue and 0.08 g/g in the lymph nodes.
No intraoperative complications occurred, but two
postoperative complications were documented, one of which
occurred in the doxorubicin group. The latter patient devel-
oped pneumonia with subsequent sternal dehiscence. The
pneumonia responded to antibiotics, and the sternal nonunion
was treated conservatively as it was asymptomatic.
None of the eight patients had a partial or complete
response to the regional chemotherapy, and all died of pro-
gressive disease 23 to 151 days after lung perfusion.
However, the results of this pilot chemotherapy study
were encouraging: the procedure was well tolerated and
reproducible, and the significant drug levels were measured
in the primary lung cancer, pulmonary metastases, and lymph
nodes. Mortality in these patients with previous unresponsive
locoregional disease was within the expected range.
Burt et al.10 described their results of ILuP with doxo-
rubicin after extensive laboratory research. Eight patients
with inoperable lung metastases from sarcoma underwent
single-lung perfusion in a phase I protocol. Again, intrapul-
monary concentrations of doxorubicin correlated with the
dose given, whereas systemic levels were minimal or unde-
tectable, but tumor levels were lower compared with lung
levels. The MTD dose for this study was defined at 40 mg/m2
of doxorubicin because an important chemical pneumonitis
developed in one patient at a dose of 80 mg/m2. On postop-
erative lung scanning, no ventilation or perfusion was present
at the perfused lung in this patient. No perioperative deaths
were encountered. There were no partial or complete re-
sponses. One patient had stabilization of disease in the per-
fused lung, whereas the lesions in the untreated lung pro-
FIGURE 1. Literature search: clinical studies on isolated
lung perfusion.
TABLE 1. Human ILuP Studies from 1995 Onward
Study Drug n
Lung
Temperature (°C)
Perfusion
Time (min)
Operable
Metastases MTD
Johnston et al.8 Doxorubicin/cisplatin 8 NA 45–60 No NA
Pass et al.12 TNF-  -interferon 15 38–39.5 90 No 6 mg
Ratto et al.13 Cisplatin 6 37 60 Yes 200 mg/m2
a
Burt et al.10 Doxorubicin 8 37 20 No 40 mg/m2
Putnam11 Doxorubicin 16 37 NA No 60 mg/m2
Schröder et al.14 Cisplatin 4 41 21–40 Both 70 mg/m2
a
Hendriks et al.15 Melphalan 16b 37, 42 30 Yes 45 mg at 42°Cc
a Fixed dose.
b 21 procedures (5 bilateral).
c In an extension trial, safe MTD was found to be 45 mg at 37°C (see text).16
MTD, maximum tolerated dose; NA, not available; TNF, tumor necrosis factor.
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gressed markedly. In the seven patients perfused with 40
mg/m2 or less of doxorubicin, there was a significant decrease
in the forced expiratory volume in 1 second and a trend
toward a significant decrease in diffusing capacity.
Subsequently, Putnam11 presented the phase I study of
isolated single-lung perfusion of doxorubicin in 16 patients
with unresectable pulmonary metastatic disease, also in sar-
coma patients.
Systemic levels were minimal or undetectable while
two patients developed a grade 4 pulmonary toxicity at a dose
of 75 mg/m2, therefore defining the MTD at 60 mg/m2 of
doxorubicin in this study. Overall operative mortality was
18.8%. One patient died of a paradoxical tumor embolus, one
of drug-related lung injury, and one of pneumonia at 3 weeks
postoperatively. Early morbidity was noted in three patients
and consisted of prolonged chest tube drainage longer than 7
days, persistent air leak longer than 7 days, and grade 4 lung
injury. Late toxicity included a decrease in forced expiratory
volume in 1 second, forced vital capacity, and a decrease in
ventilation and perfusion in the treated lung. Only one major
response occurred. Median survival time was 19.1 months in
this study.
TNF- and -Interferon
The results of ILuP with tumor necrosis factor (TNF)-
were published by Pass et al.12 in 1996, which is the only
clinical study with TNF-. Twenty patients were registered
for this phase I trial, but five patients did not have lung
perfusion. Three patients underwent resection of their metas-
tases, one procedure was aborted for mechanical reasons, and
one because of extraparenchymal pleural involvement. In the
remaining 15 patients, 16 lung perfusions were performed, 6
in the left and 10 in the right lung. One patient had staged
bilateral perfusions.
Pulmonary metastases were from soft tissue sarcoma,
melanoma, Ewing sarcoma, adenoid cystic carcinoma, renal
cell carcinoma, and colon adenocarcinoma. Lung perfusion
was performed for 90 minutes with increasing doses of
TNF- ranging from 0.3 to 6.0 mg and 0.2 mg -interferon at
moderate hyperthermia (38–39.5°C). No deaths occurred,
and no significant systemic changes in systemic blood pres-
sure or cardiac output were seen. Isolation of the lung was
complete in 10 patients with 0% leak. For a dose up to 6 mg
of TNF-, maximal systemic TNF- level was 8 ng/ml,
whereas pump-circuit levels ranged from 200 to 10976 ng/ml.
There were no operative deaths. Mean hospitalization time
was 9 days. Three patients had a short-term partial response
with progressive disease occurring after 6 to 9 months.
Cisplatin
In the study by Johnston et al.,8 two patients were
treated with cisplatin. One patient with diffuse bronchoalveo-
lar carcinoma was treated with a dose of 14 g/ml in
normothermic condition, and the other patient with metastatic
chondrosarcoma was given 20 g/ml in moderate hyperthermic
conditions. In both of them, total lung perfusion was performed
during cardiopulmonary bypass. Perfusion times were 50 and 60
minutes, respectively. Metastasectomy was not undertaken. No
patient in this study had a partial or complete response, and all
patients died within 5 months after ILuP.8
Drug levels in the two patients treated with 14 and 20
g/ml cisplatin were as follows: peak systemic, 0.44 and 0.80
g/ml; peak pulmonary perfusate, 9.34 and 10.15 g/ml;
lung, 0.69 and 0.68 g/g; tumor, 1.42 and 1.09 g/g; and
lymph node, 0.84 and 0.00 g/g, respectively.
The patient treated with 14 g/ml cisplatin developed a
pneumonia and subsequently empyema 4 days after therapy.
He required reintubation and died after 81 days. Before ILuP,
this patient had markedly diminished lung function, required
supplemental oxygen with exercise, and had been treated
unsuccessfully by a left lower lobectomy, repeated chemo-
therapy, and immunotherapy. Autopsy revealed massive tu-
mor involvement with no identifiable metastases, suggesting
that his death was most likely related to tumor progression.
Ratto et al.13 used the bimodality treatment of ILuP and
resection in six patients with lung metastases from soft tissue
sarcomas.
Major endpoints were feasibility, toxicity, and distribu-
tion of cisplatin in normal and neoplastic tissues. Inclusion
criteria were the same as the criteria generally applied for
surgical resection, that is, control of the primary tumor,
adequate pulmonary function, prediction of complete resec-
tion of metastatic disease, and no demonstrable extrapulmonary
disease. Disease-free interval and number or size of the pulmo-
nary metastases were not the exclusion criteria. Cisplatin at a
fixed, high dose of 200 mg/m2 was perfused for 60 minutes.
Lung perfusion temperature ranged from 37 to 37.5°C. Mean
pulmonary artery pressure was kept below 35 mmHg.
No patient died during or after the procedure. Two
patients developed interstitial and alveolar lung edema 48
hours after treatment, for which one patient required pro-
longed respiratory support. No systemic toxicity was ob-
served. Total cisplatin concentrations in lung plasma ex-
ceeded more than 40 times systemic plasma concentrations.
Systemic plasma cisplatin concentrations 6 and 12 hours after
treatment were 0.25 and 0.23 g/ml, respectively. There was
no difference in cisplatin lung and tumor tissue. No histologic
damage of lung specimens was observed at completion of
drug treatment. Decline in ventilatory function 10 or 30 days
after the procedure in comparison with preoperative function
was significant for forced vital capacity, forced expiratory
volume in 1 second, and carbon monoxide diffusion capacity,
although reassessments in two patients after 12 months
showed further improvement.
This particular study demonstrates that ILuP with cis-
platin is a safe and feasible technique offering a valid model
for further investigations of combined chemotherapy and
surgery in patients with pulmonary metastases.
Schro¨der et al.14 conducted a pilot study in four patients
with unilateral (n  2) and bilateral (n  2) sarcoma metas-
tases confined to a lobe or entire lung.
Metastasectomy was performed, followed by ILuP with
cisplatin at an in-flow temperature of 41°C. Eligibility in-
cluded at least four previous surgical metastasectomies, con-
trolled primary site, and no other effective treatment options
in contrast to the study by Ratto et al.13 ILuP with cisplatin at
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a fixed dose of 70 mg/m2 was given at a rate of 0.3 to 0.5
l/min for approximately 30 minutes at 41°C.
Systemic cisplatin plasma levels were low and platinum
lung uptake was 98.3 ng/mg tissue. Throughout the ILuP,
there was no evidence of drug-related systemic toxicity.
Postoperatively, all patients developed transient pulmonary
toxicity presenting as noncardiogenic edema. After a mean
follow-up of 12 months, three patients were alive and disease
free and one patient died of cerebral metastases after 13 months
without pulmonary recurrence at postmortem examination.
In this study, hyperthermic perfusion with cisplatin on
humans was also performed safely, although further investi-
gations are needed to limit pulmonary toxicity. No data on
tumor cisplatin levels or histologic changes were provided.
With regards to the multimodality approach, Schro¨der et al.14
recommend to first resect all known and resectable disease,
followed by ILuP to correctly identify metastatic disease in
an otherwise edematous lung segment.
It is difficult to make some general remarks based on so
few studies with small groups of heterogeneous patients
treated by ILuP with cisplatin. Furthermore, aforementioned
investigations differed profoundly in some aspects. For in-
stance, the patients in the study by Johnston et al.were not
treated with metastasectomy, and Schro¨der et al. and Ratto et
al. were investigating two different groups of patients: those
with resectable pulmonary metastases and those without any
treatment options left, making any conclusions fragile, espe-
cially on survival data. Concerning pharmacokinetics, Ratto
et al. has treated his patients with almost thrice the amount of
cisplatin compared with Schro¨der et al. without short-term
histologic damage.
Melphalan
Until now, only one phase I study was performed to
determine the MTD of melphalan in clinical ILuP.15 In total,
21 procedures were performed in 16 patients. Escalating dose
schedules of melphalan were used at a temperature of 37 and
42°C. Perfusion time was 30 minutes, and only operable lung
metastases were included. All procedures were performed
without technical difficulties. Operative mortality was 0%,
and no systemic toxicity was encountered. Grade 3 pulmo-
nary toxicity developed at a dose of 60 mg of melphalan at
37°C; so, the MTD was found to be 45 mg at 42°C.
In an extension trial of this study, more toxicity was
observed with a perfusion temperature of 42°C.16 So, a safe
MTD should be set at 45 mg of melphalan at 37°C. Pharma-
cokinetic studies in this phase I trial showed a significant
correlation between perfused melphalan dose, perfusate area
under the concentration-time curve, and lung tissue melpha-
lan concentrations.17,18 However, there was no correlation
between melphalan dose and tumor tissue concentrations.
The peak concentration and area under the curve of melpha-
lan were 250- and 10-fold higher than in the systemic circu-
lation, respectively. Long-term 5-year overall survival in this
trial was 54.8  10.6%m and median disease-free survival
was 19 months (95% confidence interval 4.4–33.6).19
RECOMMENDATION
What is the current role of locoregional chemotherapy
for lung metastases? A lot of experimental data support the
application of clinical ILuP or pulmonary artery infusion. At
the present time, only phase I trials have been completed, so
these techniques should still be considered to be experimen-
tal. For this reason, they should be limited to centers with a
special interest and expertise in a regional therapy for lung
metastases. Further, international collaboration in performing
phase II and phase III trials should be encouraged.
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